Tyme, Eagle join forces to advance SM-88 in advanced cancers

This article was originally published here

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt

The post Tyme, Eagle join forces to advance SM-88 in advanced cancers appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply